Patents by Inventor Juan BAYO

Juan BAYO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF JUMONJI C DEMETHYLASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY RESISTANCE AND RADIORESISTANCE IN CANCER
    Publication number: 20230255951
    Abstract: Disclosed are methods for the use of Jumonji C demethylase inhibitors for the radiosensitization of cancers cells and the treatment and prevention of chemotherapy resistance in cancer.
    Type: Application
    Filed: November 14, 2022
    Publication date: August 17, 2023
    Inventors: Maithili P. DALVI, Elisabeth D. MARTINEZ, John D. MINNA, Juan BAYO-FINA, Amit DAS
  • Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer
    Patent number: 11497740
    Abstract: Disclosed are methods for the use of Jumonji C demethylase inhibitors for the radiosensitization of cancers cells and the treatment and prevention of chemotherapy resistance in cancer.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 15, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maithili P Dalvi, Elisabeth D Martínez, John D Minna, Juan Bayo-Fina, Amit Das
  • Compositions and methods for increasing mesenchymal stromal cell migration to tumors
    Patent number: 11173180
    Abstract: The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: November 16, 2021
    Assignee: Consejo National de Investigaciones Cientificas y Tecnicas (CONICET)
    Inventors: Guillermo Daniel Mazzolini, Mariana Gabriela Garcia, Juan Bayo
  • USE OF JUMONJI C DEMETHYLASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY RESISTANCE AND RADIORESISTANCE IN CANCER
    Publication number: 20190151296
    Abstract: Disclosed are methods for the use of Jumonji C demethylase inhibitors for the radiosensitization of cancers cells and the treatment and prevention of chemotherapy resistance in cancer.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 23, 2019
    Inventors: Maithili P DALVI, Elisabeth D MARTINEZ, John D MINNA, Juan BAYO-FINA, Amit DAS
  • COMPOSITIONS AND METHODS FOR INCREASING MESENCHYMAL STROMAL CELL MIGRATION TO TUMORS
    Publication number: 20190022143
    Abstract: The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.
    Type: Application
    Filed: February 9, 2018
    Publication date: January 24, 2019
    Inventors: Guillermo Daniel MAZZOLINI, Mariana Gabriela GARCIA, Juan BAYO
  • COMPOSITIONS AND METHODS FOR INCREASING MESENCHYMAL STROMAL CELL MIGRATION TO TUMORS
    Publication number: 20160220612
    Abstract: The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.
    Type: Application
    Filed: September 5, 2014
    Publication date: August 4, 2016
    Inventors: Guillermo Daniel MAZZOLINI, Mariana Gabriela GARCIA, Juan BAYO